Neurobiological Technologies, Inc. (OTCPK: NTII)
Health Care · Biotechnology · US
$0.00
— today · -99.0% 1Y
Neurobiological Technologies, Inc. (OTCPK: NTII) operates in the Biotechnology industry within the Health Care sector. The company is valued at $27.00 and employs 4 people.
Over the last twelve months the share price has lost 99.0%, trading between 0.00 and 0.00.
Tweenvest scores Neurobiological Technologies, Inc. across four factors: value 50/100. Its strongest factor is value.
NTII price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $27.00
- Revenue (TTM)
- $25.32M
- P/E
- 0.00
- EPS
- 0.69
- Dividend yield
- —
- Beta (5Y)
- -501.55
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 27.02M
- Employees
- 4
- Next earnings
- —
About Neurobiological Technologies, Inc.
Neurobiological Technologies, Inc. (NTII) is currently undergoing a liquidation and dissolution process, a plan that received stockholder endorsement in October 2009. In its earlier operations, the company's core focus was on the development of experimental pharmaceutical treatments for various human ailments. This firm, which was established in 1987, has its primary location in Emeryville, California.
- ISIN
- US64124W3043
- Founded
- 1987
- Listed since
- Oct 31, 1994
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $264.96 | +1.20% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $439.33 | +1.29% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $146.12 | +1.86% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.05 | +1.44% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $834.04 | +0.90% |
| argenx SEENXTBR: ARGX | $65.85B | €902.00 | +1.90% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $145.13 | +0.04% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.